Latest Breaking News On - Myelodysplastic syndromes - Page 1 : comparemela.com

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status Durable and sustained red blood cell.

Johna scarlettDrug administrationExchange commissionGeron corporation nasdaqMalignant hematology departmentMoffitt cancer centerPatient support programGeron corporationChief executiveRami komrokjiVice chairConference callEastern timePrescribing informationMedication guidePrivate securities litigation reform act

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem.

United statesUnited kingdomCity ofOlivia manserElias jabbourSusana noonanJulia wilsonDepartment of leukemiaDivision of cancer medicineSa noonan communicationsMd anderson cancer centerAmerican society of clinical oncologyExchange commissionSaturday juneB cell acute lymphoblastic leukemiaClinical oncology

Autolus presents FELIX data at ASCO | Company Announcement

Autolus presents FELIX data at ASCO | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofSusana noonanJulia wilsonChris hollowoodOlivia manserCollins fergus wittBen atwell tim stamperElias jabbourSyncona investment managementDepartment of leukemiaExchange commissionAutolus therapeutics plcAmerican society of clinical oncologySa noonan communications

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongUnited statesYuxiang maHaibo qiuMasa lasicaPrnewswire ascentage pharmaHuafeng wangAscentage pharmaYifan zhaiMd anderson cancer centerAmerican society of clinical oncologySun yat sen university cancer centerZhejiang university school of medicineMajor nationalDana farber cancer instituteChina national medical products administration

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone